The US Food and Drug Administration (FDA) has approved United States-based Regeneron Pharmaceuticals' and France-based Sanofi's Dupixent (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, it was reported yesterday.
The product can be utilised with or without topical corticosteroids. It is a targeted biologic therapy that inhibits signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two key proteins that are likely to play a central role in type two inflammation that underlies atopic dermatitis and several other allergic diseases. It was also granted Breakthrough Therapy designation by the US FDA for inadequately controlled moderate-to-severe atopic dermatitis in adolescents. The Breakthrough Therapy designation was created to accelerate the development and review of drugs developed for serious or life-threatening conditions.
The US FDA assessed the product application under Priority Review, which is reserved for medicines that represent potentially significant improvements in safety or efficacy in treating serious conditions.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins